Beacon Medical Interchange

beaconmedic.com

 

Beacon Medical Interchange
Avatar

KEYNOTE-189: Clinical Implications in Patients with Less Than 1% Tumor PD-L1 Expression

By Beacon Medical Interchange FEATURING Jack West
By Beacon Medical Interchange FEATURING Jack West
19 views
November 2, 2018
Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and negative (sub ...
read more ↘
0 Comments
Login to view comments. Click here to Login

Featured Video

21:09
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Featured Video

20:59
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam
Lung
14:11
Beacon Medical Interchange

Key Findings From Study on Plasma-Based TMB as a Predictive Biomarke…

Feat. J. West, C. Aggarwal
08:34
Beacon Medical Interchange

Status of TMB as a Biomarker in NSCLC & Clinical Utility of Nega…

Feat. J. West, C. Aggarwal
09:09
Beacon Medical Interchange

Best Treatment First: Implications for Front - Loading Combinations …

Feat. J. West
09:07
Beacon Medical Interchange

How do Patients with Advanced NSCLC on Daily Steroids Do on Immune C…

Feat. J. West
07:05
Beacon Medical Interchange

FDA Approval of Dacomitinib for NSCLC - Is it the Gamechanger in the…

Feat. J. West
10:16
Beacon Medical Interchange

Is Progression-Free Survival without Overall Survival Benefit Enough?

Feat. J. West
07:12
Beacon Medical Interchange

Small Trial Shows Big Risks of First Line Pembro to EGFR Mutation-Po…

Feat. J. West
08:57
Beacon Medical Interchange

Nivo/Ipi Rx of Choice for Adv. NSCLC, PD-L1 Under 1%, High TMB? New …

Feat. J. West
09:33
Beacon Medical Interchange

Practice Changing Positive Keytruda Trial : Chemo +IO had significan…

Feat. J. West
11:06
Beacon Medical Interchange

KEYNOTE-042: Should Pembrolizumab Replace Chemo for Broader Populati…

Feat. J. West
10:18
Beacon Medical Interchange

My Top 5 ASCO 2018 Abstracts in Advanced NSCLC

Feat. J. West
07:13
Beacon Medical Interchange

My Top 5 ASCO 2018 Abstracts in Stage I-III NSCLC, Small Cell Lung C…

Feat. J. West
15:37
Beacon Medical Interchange

Local Therapy for Advanced NSCLC: Revising Outdated Principles for S…

Feat. J. West
12:38
Beacon Medical Interchange

Is Chemo the Key for EGFR Mutation-Positive NSCLC? The Data Too Good…

Feat. J. West
08:10
Beacon Medical Interchange

IMpower131: Role for Carbo/Nab-Paclitaxel/Atezolizumab Combo for Adv…

Feat. J. West
13:08
Beacon Medical Interchange

Nivo/Ipi vs. Chemo in High TMB Advanced NSCLC: Key Results from Chec…

Feat. J. West
09:40
Beacon Medical Interchange

Are TMB and Nivolumab/Ipilimumab Ready for Clinical Use? Insights fr…

Feat. J. West
06:32
Beacon Medical Interchange

KEYNOTE-189: Clinical Implications in Patients with Less Than 1% Tum…

Feat. J. West
06:16
Beacon Medical Interchange

KEYNOTE-189: Clinical Implications in Patients with Low (1-49%) Tumo…

Feat. J. West
07:59
Beacon Medical Interchange

KEYNOTE-189: Clinical Implications for High Tumor PD-L1 Expression

Feat. J. West
05:03
Beacon Medical Interchange

Is Chemotherapy More Effective After Prior Immunotherapy?

Feat. J. West
11:35
Beacon Medical Interchange

New Insights on Acq. Resistance to Immune Checkpoint Inhibitors for …

Feat. J. West
13:06
Beacon Medical Interchange

Pembro + Chemo in Metastatic NSCLC - Key Summary of a Practice-Chang…

Feat. J. West
09:15
Beacon Medical Interchange

Chemo/Immunotherapy in Advanced Squamous NSCLC: What is the Impact o…

Feat. J. West
06:36
Beacon Medical Interchange

Afatinib in Patients With Uncommon EGFR Mutations In NSCLC

Feat. J. West
07:21
Beacon Medical Interchange

How Should We Monitor Patients After Potentially Curative Lung Cance…

Feat. J. West
07:01
Beacon Medical Interchange

Diminishing Returns after a Fixed Duration of Immunotherapy Treatmen…

Feat. J. West
02:40
Beacon Medical Interchange

Is There Still a Value in Testing for PD-L1 Expression in Advanced N…

Feat. J. West
03:35
Beacon Medical Interchange

Better Communication Leads to Better Outcomes for Cancer Patients

Feat. J. West
06:24
Beacon Medical Interchange

Are Two Immunotherapy Agents Better than One? Was the MYSTIC Trial a…

Feat. J. West
10:26
Beacon Medical Interchange

Is Immunotherapy Ineffective for Driver Mutation-positive Advanced N…

Feat. J. West
06:33
Beacon Medical Interchange

Is Durvalumab Curing Patients or Just Treating Metastatic Disease Ea…

Feat. J. West
07:44
Beacon Medical Interchange

Durvalumab (Imfinzi) FDA Approved for Stage III NSCLC: Standard of C…

Feat. J. West
08:13
Beacon Medical Interchange

Has the KEYNOTE-189 Trial Defined a Clear Standard of Care in Metast…

Feat. J. West
10:20
Beacon Medical Interchange

Is There a Better Lung Immunotherapy Biomarker than PD-L1?

Feat. J. West
11:29
Beacon Medical Interchange

Atezolizumab in First Line Metastatic NSCLC: Early Clinical Results …

Feat. J. West
08:55
Beacon Medical Interchange

Genomic Sequencing for All Solid Tumors: Where Will This Lead Us?

Feat. J. West
06:25
Beacon Medical Interchange

Dabrafenib/Trametinib for BRAF V600E Mutation-Positive Advanced NSCLC

Feat. J. West
11:47
Beacon Medical Interchange

Osimertinib as First-Line Treatment for EGFR Mutation-Positive Advan…

Feat. J. West
07:54
Beacon Medical Interchange

Dacomitinib: Dark Horse EGFR TKI Charges into First Line Setting for…

Feat. J. West
05:53
Beacon Medical Interchange

Are PD-1/PD-L1 Immune Checkpoint Inhibitors Completely Interchangeab…

Feat. J. West
07:02
Beacon Medical Interchange

Will Immunotherapy Shift Treatment Balance for Borderline Resectable…

Feat. J. West
10:03
Beacon Medical Interchange

Research Question or Standard of Care: The Barriers to Broad Adoptio…

Feat. J. West
07:22
Beacon Medical Interchange

Hyper-Progressive Disease on Immunotherapy in Advanced NSCLC

Feat. J. West
09:09
Beacon Medical Interchange

Tumor Mutational Burden in SCLC: A Valuable Immunotherapy Biomarker?

Feat. J. West
06:56
Beacon Medical Interchange

Chemo/Immunotherapy Data Increasingly Compelling with Additional Fol…

Feat. J. West
09:36
Beacon Medical Interchange

The FLAURA Trial: Practice-Changing Results for EGFR Mutation-Positi…

Feat. J. West
06:20
Beacon Medical Interchange

Immunotherapy in Stage III NSCLC: Practice-Changing Results of PACIF…

Feat. J. West
04:51
Beacon Medical Interchange

Early Returns on FLAURA Trial: Osimertinib as First Line Agent in EG…

Feat. J. West
04:19
Beacon Medical Interchange

Immunotherapy in Locally Advanced NSCLC - PACIFIC Study Shows Durval…

Feat. J. West
07:19
Beacon Medical Interchange

IMpower133: Is there Finally a New Standard of Care for Extensive St…

Feat. J. West
07:22
Beacon Medical Interchange

Updated Results on PACIFIC Trial: Revise Who Should Receive Consolid…

Feat. J. West
08:04
Beacon Medical Interchange

Long-Term Management on Immunotherapy for Advanced NSCLC: Insights f…

Feat. J. West
04:14
Beacon Medical Interchange

Pembrolizumab for PS2 Patients with Adv. NSCLC: Results of the PePS2…

Feat. J. West
06:39
Beacon Medical Interchange

The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape?

Feat. J. West
09:43
Beacon Medical Interchange

The MYSTIC Trial has Failed on OS in Advanced NSCLC: What Does and D…

Feat. J. West
09:54
Beacon Medical Interchange

OS for Local Ablative Therapy for Oligometastatic NSCLC: Does it Fit…

Feat. J. West
09:59
Beacon Medical Interchange

Chemotherapy With or Without Immunotherapy in Stage IV Non-squamous …

Feat. J. West
08:59
Beacon Medical Interchange

Nivolumab vs. Chemo in Relapsed SCLC (review of Checkmate-331 trial)

Feat. J. West
13:29
Beacon Medical Interchange

Top 5 Most Influential Trial Findings in Lung Cancer Management in 2…

Feat. J. West
20:37
Beacon Medical Interchange

What is the Optimal Duration for Immunotherapy in Responding Patient…

Feat. J. West, D. Spigel
19:08
Beacon Medical Interchange

Changes in Lung Cancer Management, Addressing Stigma, and the Rise o…

Feat. J. Schiller, J. West
25:18
Beacon Medical Interchange

Overcoming Barriers in Cancer Care Delivery, Smoking Cessation, and …

Feat. G. Morgan, J. West
19:06
Beacon Medical Interchange

Weighing Clinical Significance of New Clinical Trial Results With Im…

Feat. J. West, C. Langer
25:42
Beacon Medical Interchange

Chest CT Screening and Pulmonary Workups in Lung Cancer Beyond Terti…

Feat. J. West, J. Gorden
20:09
Beacon Medical Interchange

Defining the Role of Interventional Pulmonology in Lung Cancer Manag…

Feat. J. West, J. Gorden
20:09
Beacon Medical Interchange

Why is Broader FDA Approval of First Pembrolizumab Monotherapy (KEYN…

Feat. J. West
26:53
Beacon Medical Interchange

Growing Momentum for Plasma-based Next Generation Sequencing in Adva…

Feat. J. West, C. Aggarwal
19:58
Beacon Medical Interchange

Current Practice & Challenges in Execution of Genomic Testing in…

Feat. J. West, G. Riely
28:12
Beacon Medical Interchange

Should Local Ablation Therapy in Oligometastatic or Oligoprogressing…

Feat. J. West, G. Riely
18:01
Beacon Medical Interchange

Critical Review of Combining Radiation with Immunotherapy in Advance…

Feat. J. West
31:09
Beacon Medical Interchange

Open Questions in Radiation Oncology Care: From Proton Beam Radiatio…

Feat. J. West, D. Palma
12:47
Beacon Medical Interchange

Immunotherapy-Based Options for NSCLC: How to Decide Which Approach …

Feat. J. West, C. Aggarwal